Paliperidone Palmitate: A Breakthrough Treatment for Schizophrenia? A Review on Patient Adherence Levels, Healthcare Resource Utilization and Costs

References

• Correll CU, Martin A, Patel C, et al. Systematic literature review of schizophrenia clinical practice guidelines on acute and maintenance management with antipsychotics. Schizophrenia. 2022;8(1):5. PMID: 35210430; PMCID: PMC8873492. doi:10.1038/s41537-021-00192-x
   Web of Science ®Google Scholar
• Bright CE. Measuring medication adherence in patients with schizophrenia: an integrative review. Arch Psychiatr Nurs. 2017;31(99–110):10. doi:10.1016/j.apnu.2016.09.003
   Google Scholar
• De Las Cuevas C, de Leon J, Penate W, et al. Factors influencing adherence to psychopharmacological medications in psychiatric patients: a structural equation modeling approach. Patient Prefer Adherence. 2017;11:681–690. doi:10.2147/PPA.S133513
   PubMed Web of Science ®Google Scholar
• El-Mallakh P, Findlay J. Strategies to improve medication adherence in patients with schizophrenia: the role of support services. Neuropsychiatr Dis Treat. 2015;11(1077–90):13.
   Google Scholar
• García S, Martínez-Cengotitabengoa M, López-Zurbano S, et al. Adherence to antipsychotic medication in bipolar disorder and schizophrenic patients: a systematic review. J Clin Psychopharmacol. 2016;36(4):355–371. doi:10.1097/JCP.0000000000000523
   PubMed Web of Science ®Google Scholar
• Lafeuille M-H, Frois C, Cloutier M, et al. Factors associated with adherence to the HEDIS quality measure in Medicaid patients with schizophrenia. Am Health Drug Benefits. 2016;9(399–410):8.
   Google Scholar
• Velligan DI, Sajatovic M, Hatch A, et al. Why do psychiatric patients stop antipsychotic medication? A systematic review of reasons for nonadherence to medication in patients with serious mental illness. Patient Prefer Adherence. 2017;11(449–68):9. doi:10.2147/PPA.S124658
   Google Scholar
• Yang J, Ko Y-H, Paik J-W, et al. Symptom severity and attitudes toward medication: impacts on adherence in outpatients with schizophrenia. Schizophr Res. 2012;134(226–31):11. doi:10.1016/j.schres.2011.11.008
   Google Scholar
• Emsley R, Chiliza B, Asmal L, Harvey BH. The nature of relapse in schizophrenia. BMC Psychiatry. 2013;13:50. PMID: 23394123; PMCID: PMC3599855. doi:10.1186/1471-244X-13-50
   PubMed Web of Science ®Google Scholar
• Kane JM, Kishimoto T, Correll CU. Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies. World Psychiatry. 2013;12(3):216–226. PMID: 24096780; PMCID: PMC3799245. doi:10.1002/wps.20060
   PubMed Web of Science ®Google Scholar
• Kim J, Ozzoude M, Nakajima S, et al. Insight and medication adherence in schizophrenia: an analysis of the CATIE trial. Neuropharmacology. 2020;168:107634. PMID: 31077729. doi:10.1016/j.neuropharm.2019.05.011
   PubMed Web of Science ®Google Scholar
• Leucht S, Heres S. Epidemiology, clinical consequences, and psychosocial treatment of nonadherence in schizophrenia. J Clin Psychiatry. 2006;67:3–8. PMID: 16822090.
   PubMed Web of Science ®Google Scholar
• Correll CU, Citrome L, Haddad PM, et al. The use of long-acting injectable antipsychotics in schizophrenia: evaluating the evidence. J Clin Psychiatry. 2016;77(suppl 3):1–24. PMID: 27732772. doi:10.4088/JCP.15032su1
   PubMed Web of Science ®Google Scholar
• Kishimoto T, Hagi K, Kurokawa S, et al. Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre–post studies. Lancet Psychiatry. 2021;8:387. doi:10.1016/S2215-0366(21)00039-0
   PubMed Web of Science ®Google Scholar
• Lin D, Thompson-Leduc P, Ghelerter I, et al. Real-world evidence of the clinical and economic impact of long-acting injectable versus oral antipsychotics among patients with schizophrenia in the United States: a systematic review and meta-analysis. CNS Drugs. 2021;35(5):469–481. doi:10.1007/s40263-021-00815-y
   PubMed Web of Science ®Google Scholar
• Markowitz M, Fu DJ, Levitan B, et al. Long-acting injectable paliperidone palmitate versus oral paliperidone extended release: a comparative analysis from two placebo-controlled relapse prevention studies. Ann Gen Psychiatry. 2013;12:22. doi:10.1186/1744-859X-12-22
   PubMed Web of Science ®Google Scholar
• Hsia SL, Leckband SG, Rao S, et al. Dosing strategies for switching from oral risperidone to paliperidone palmitate: effects on clinical outcomes. Ment Health Clin. 2017;7:95–100. doi:10.9740/mhc.2017.05.095
   PubMedGoogle Scholar
• Shah A, Xie L, Kariburyo F, et al. Treatment patterns, healthcare resource utilization and costs among schizophrenia patients treated with long-acting injectable versus oral antipsychotics. Adv Ther. 2018;35:1994–2014. doi:10.1007/s12325-018-0786-x
   PubMed Web of Science ®Google Scholar
• Manjelievskaia J, Amos TB, El Khoury AC, et al. A comparison of treatment patterns, healthcare resource utilization, and costs among young adult Medicaid beneficiaries with schizophrenia treated with paliperidone palmitate or oral atypical antipsychotics in the US. J Med Econ. 2018;21:1221–1229. doi:10.1080/13696998.2018.1527608
   PubMed Web of Science ®Google Scholar
• Correll CU, Kim E, Sliwa JK, et al. Pharmacokinetic characteristics of long-acting injectable antipsychotics for schizophrenia: an overview. CNS Drugs. 2021;35(1):39–59. PMID: 33507525; PMCID: PMC7873121. doi:10.1007/s40263-020-00779-5
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. The American Psychiatric Association Practice Guideline for the Treatment of Patients with Schizophrenia. Virginia, US: American Psychiatric Association; 2020.
   Google Scholar
• Remington G, Addington D, Honer W, et al. Guidelines for the pharmacotherapy of schizophrenia in adults. Can J Psychiatry. 2017;62(9):604–616. doi:10.1177/0706743717720448
   PubMed Web of Science ®Google Scholar
• Mathews M, Gopal S, Nuamah I, et al. Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia. Neuropsychiatr Dis Treat. 2019;15:1365–1379. PMID: 31190840; PMCID: PMC6535080. doi:10.2147/NDT.S197225
   PubMed Web of Science ®Google Scholar
• Rosso G, Pessina E, Martini A, Di Salvo G, Maina G. Paliperidone palmitate and metabolic syndrome in patients with schizophrenia: a 12-month observational prospective cohort study. J Clin Psychopharmacol. 2016;36(3):206–212. PMID: 27043122. doi:10.1097/JCP.0000000000000494
   PubMed Web of Science ®Google Scholar
• Najarian D, Sanga P, Wang S, et al. A randomized, double-blind, multicenter, noninferiority study comparing paliperidone palmitate 6-month versus the 3-month long-acting injectable in patients with schizophrenia. Int J Neuropsychopharmacol. 2022;25(3):238–251. PMID: 34791283; PMCID: PMC8929757. doi:10.1093/ijnp/pyab071
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097. PMID: 19621072; PMCID: PMC2707599. doi:10.1371/journal.pmed.1000097
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010;8(5):336–341. doi:10.1016/j.ijsu.2010.02.007
   PubMed Web of Science ®Google Scholar
• Anderson JP, Icten Z, Alas V, Benson C, Joshi K. Comparison and predictors of treatment adherence and remission among patients with schizophrenia treated with paliperidone palmitate or atypical oral antipsychotics in community behavioral health organizations. BMC Psychiatry. 2017;17(1):346. PMID: 29047368; PMCID: PMC5648472. doi:10.1186/s12888-017-1507-8
   PubMedGoogle Scholar
• Campagna EJ, Muser E, Parks J, Morrato EH. Methodological considerations in estimating adherence and persistence for a long-acting injectable medication. J Manag Care Spec Pharm. 2014;20(7):756–766. PMID: 24967528. doi:10.18553/jmcp.2014.20.7.756
   PubMed Web of Science ®Google Scholar
• Patel C, Emond B, Morrison L, et al. Risk of subsequent relapses and corresponding healthcare costs among recently-relapsed Medicaid patients with schizophrenia: a real-world retrospective cohort study. Curr Med Res Opin. 2021;37(4):665–674; PMID: 33507831. doi: 10.1080/03007995.2021.1882977
   PubMed Web of Science ®Google Scholar
• Young-Xu Y, Duh MS, Muser E, et al. Impact of paliperidone palmitate versus oral atypical antipsychotics on health care resource use and costs in veterans with schizophrenia. J Clin Psychiatry. 2016;77(10):e1332–e1341. PMID: 27574835. doi:10.4088/JCP.16m10745
   PubMed Web of Science ®Google Scholar
• Greene M, Yan T, Chang E, Hartry A, Touya M, Broder MS. Medication adherence and discontinuation of long-acting injectable versus oral antipsychotics in patients with schizophrenia or bipolar disorder. J Med Econ. 2018;21(2):127–134. PMID: 28895758. doi:10.1080/13696998.2017.1379412
   PubMed Web of Science ®Google Scholar
• Pesa JA, Doshi D, Wang L, Yuce H, Baser O. Health care resource utilization and costs of California Medicaid patients with schizophrenia treated with paliperidone palmitate once monthly or atypical oral antipsychotic treatment. Curr Med Res Opin. 2017;33(4):723–731. PMID: 28044455. doi:10.1080/03007995.2016.1278202
   PubMed Web of Science ®Google Scholar
• Wang H, Zhang Y, Liu J, et al. Persistence with and adherence to paliperidone palmitate once-monthly injection for schizophrenia treatment in China and Japan. J Clin Psychiatry. 2021;83(1):13850. PMID: 34963203. doi:10.4088/JCP.20m13850
   Web of Science ®Google Scholar
• Pilon D, Tandon N, Lafeuille MH, et al. Treatment patterns, health care resource utilization, and spending in Medicaid beneficiaries initiating second-generation long-acting injectable agents versus oral atypical antipsychotics. Clin Ther. 2017;39(10):1972–1985.e2; PMID: 28919292. doi: 10.1016/j.clinthera.2017.08.008
   PubMed Web of Science ®Google Scholar
• Joshi K, Muser E, Xu Y, Schwab P, Datar M, Suehs B. Adherence and economic impact of paliperidone palmitate versus oral atypical antipsychotics in a Medicare population. J Comp Eff Res. 2018;7(8):723–735. PMID: 29722547. doi:10.2217/cer-2018-0003
   PubMed Web of Science ®Google Scholar
• El Khoury A, Patel C, Huang A, Wang L, Bashyal R. Transitioning from oral risperidone or paliperidone to once-monthly paliperidone palmitate: a real-world analysis among Veterans Health Administration patients with schizophrenia who have had at least one prior hospitalization. Curr Med Res Opin. 2019;35(12):2159–2168. PMID: 31366251. doi:10.1080/03007995.2019.1651129
   PubMed Web of Science ®Google Scholar
• Schneider-Thoma J, Chalkou K, Dörries C, et al. Comparative efficacy and tolerability of 32 oral and long-acting injectable antipsychotics for the maintenance treatment of adults with schizophrenia: a systematic review and network meta-analysis. Lancet. 2022;399(10327):824–836. PMID: 35219395. doi:10.1016/S0140-6736(21)01997-8
   PubMed Web of Science ®Google Scholar